Earnings are upon us
As the air chills and the leaves change, analysts are preparing only their greatest great-quarters for guys across the world of biotech, for earnings season has returned. Here’s what we’re looking out for this week:
- Biogen, which will present this morning, faces two perennial questions: Just how fast is revenue of the rare disease drug Spinraza growing, and just how slowly are sales of multiple sclerosis treatments shrinking? This quarter’s answers will set the tone for the Biogen narrative.
- Sarepta Therapeutics, presenting Wednesday, has a three-digit stock price because of its perceived future in gene therapy, but no one’s quite sure how long its sole product, Exondys 51, can grow before hitting a plateau. The drug, for a form of Duchenne muscular dystrophy, has had an admirable launch, but each quarter invites scrutiny of its long-term trajectory.
- Gilead Sciences, up Thursday, is about two months away from having no CEO. John Milligan is stepping down at the end of the year after taking the job in 2016, and you can bet the world will have some questions for Gilead about how the search for his replacement is coming along.
No hay comentarios:
Publicar un comentario